Fractyl's Novel Diabetes Treatment Clears First Hurdle In Clinical Trial
Executive Summary
The first-in-human study of Fractyl's Revita duodenal mucosal resurfacing system shows significant short-term improvement in hyperglycemia in patients with type 2 diabetes, with few adverse events.